Sign In
Buy DCPH
$25.59
+0 (+0%)
At Close: Sep 09, 2024
Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat
09:31am, Wednesday, 07'th Feb 2024
Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve
Deciphera: Upside Potential For The Patient Investor
04:37am, Tuesday, 09'th Jan 2024
Deciphera Pharmaceuticals has seen a 50% upside with successful phase 3 trial results. DCPH has achieved positive data in a subpopulation of patients with KIT exon 11 primary mutation. The company's p
Deciphera Pharmaceuticals: Moving The Needle Where It Counts
11:48pm, Sunday, 07'th Jan 2024
Deciphera Pharmaceuticals continues to make progress with its flagship drug ripretinib, with positive phase 3 results and ongoing trials. They are also working on commercializing the CSF1R inhibitor v
Deciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 02'nd Jan 2024
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve
Deciphera (DCPH) Stock Gains 17% on Q3 Earnings & Sales Beat
09:01am, Tuesday, 31'st Oct 2023
Deciphera (DCPH) reports better-than-expected third-quarter 2023 results, wherein earnings and revenues beat estimates, driven by increased Qinlock sales. The stock rises 17%.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
09:46am, Monday, 30'th Oct 2023
Deciphera Pharmaceuticals, Inc. (DCPH) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.55 per share a year ago.
Deciphera Pharmaceuticals: Clawing Its Way Back
05:06am, Tuesday, 22'nd Aug 2023
Deciphera Pharmaceuticals is focused on the development of their multikinase inhibitor ripretinib for the treatment of gastrointestinal stromal tumor. The INSIGHT study is comparing ripretinib against
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
07:43pm, Monday, 21'st Aug 2023
Biotech stocks may offer some of the most explosive opportunities on the market. For one, we have millions of baby boomers demanding better care.
3 Under-the-Radar Biotech Stocks to Buy in 2023
07:40am, Saturday, 19'th Aug 2023
Deciphera Pharmaceuticals' lead therapy is Qinlock, to treat gastrointestinal stromal tumors. Mirati Therapeutics' Krazati is showing promise as a part of a combination therapy.
Why Shares of Deciphera Pharmaceuticals Rose This Week
03:30pm, Friday, 11'th Aug 2023
Deciphera saw revenue rise by 17.4% year over year. The company's only marketed therapy is Qinlock to treat advanced GIST.
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
09:15am, Thursday, 10'th Aug 2023
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.
Deciphera Is A Buy In Expectation Of A Significant Comeback
07:02am, Sunday, 18'th Jun 2023
After a period of bad news, DCPH has slowly inched back into a positive period. They have a lot of good news and some upcoming catalysts. Current prices make it quite attractive.
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 3.6% Since Last Earnings Report?
12:39pm, Friday, 02'nd Jun 2023
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
07:00am, Monday, 08'th May 2023
WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve
